| |
著者: Ciccone N, Kovacheff MB, Frey BN.
雑誌名: Expert Opin Pharmacother. 2023 Jan;24(1):145-151. doi: 10.1080/14656566.2022.2114345. Epub 2022 Aug 22.
Abstract/Text
INTRODUCTION: Premenstrual dysphoric disorder (PMDD) is a prevalent psychiatric condition associated with substantial mental distress, impaired psychosocial functioning, high rates of co-morbid psychiatric conditions, and elevated risk of suicide.
AREAS COVERED: We provide an update on epidemiology, pathophysiology, clinical presentation, and diagnosis of PMDD, with a focus on the pharmacological management of this condition.
EXPERT OPINION: Given the high rates of false positives from retrospective assessments, prospective daily symptom monitoring for a minimal of two symptomatic menstrual cycles is critical to accurately confirm (or rule out) the diagnosis of PMDD. Serotonin-based antidepressants are well-established first-line treatments of PMDD. Second-line treatment includes the use of combined, monophasic oral contraceptives. In mild to moderate cases, independent meta-analyses have shown efficacy of Chasteberry extract (Vitex agnus cactus). Preliminary results with compounds blocking the synthesis of allopregnanolone are promising.
PMID 35974667 Expert Opin Pharmacother. 2023 Jan;24(1):145-151. doi: 10.1080/14656566.2022.2114345. Epub 2022 Aug 22.
|
